Disclosure under SEBI (PIT) Regulations
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Limited disclosed changes in shareholding by its promoters and directors under SEBI (PIT) Regulations, 2015. Managing Director S Nagi Reddy acquired 72,600 equity shares through a preferential allotment on 20 November 2025, increasing his holding from 23.26%. Other promoters/directors — S Koni Reddy and another promoter — each acquired 54,450 equity shares along with warrants (around 4.99 lakh warrants each) via the same preferential route. All transactions were purchases carried out on a preferential basis, with intimation given on 21 November 2025. The disclosure was filed in Form C as required under Regulation 7(2) read with Regulation 6(2).
Positive signal for shareholders — promoters and directors are deepening their stake through a preferential issue, indicating insider confidence in the company's growth. The move also means existing public shareholders face further dilution, with the promoter group absorbing the bulk of the new issuance.